WARRINGTON, Pa., Jan. 26, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (NasdaqNM:DSCO - News) announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Discovery’s lead product, Surfaxin(r), for the prevention and treatment of Bronchopulmonary Dysplasia (BPD, also known as Chronic Lung Disease) in premature infants.
